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We believe practitioners in tropical health centres
should be aware of such complication, and an active in-
vestigation of the neurological side effects is needed. In
case of inefficient initial treatment, documenting malarial
infection is necessary before starting a multimolecular
therapy.
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Response of patients with sickle cell anaemia and end-
stage renal disease to erythropoietin treatment
Sir,
Generally, end-stage renal disease (ESRD) due to sickle
cell anaemia (SCA) occurs in <1% of patients receiving
renal replacement treatment. For this reason, data about
this patient group are very limited and controversial. Both
the unresponsiveness of erythropoietin (Epo) treatments
Table 1. Characteristics by outcome (AHRF vs. improvement) groups
Variable
Artemisinin-based combination-treated patients
P
Death Survivor
n =1 2 n =3 4
Age [years, mean (SD)] 35.9 (10.2) 31.4 (11.4) 0.2
Male 75% 79.4% 0.5
Artemisinin-based combination with
Lumefantrine 58.3% 38.2% 0.3
Amodiaquine 25% 39.4% 0.5
Mefloquine 0% 17.6% 0.3
Piperaquine/triméthoprim 16.6% 14.7% 1
Artemisinin treatment duration [day, mean (SD)] 2.9 (0.3) 2.8 (0.5) 0.46
Delay between drug starting and AHRF
[day, mean (SD)]
3.5 (4.0) 2.3 (1.5) 0.6
Concomitant prescribed drugs
Quinine 66.6% 70.6% 0.5
Paracetamol 25% 41.2% 0.5
Antibiotic 50% 47.1% 1
Coma on admission 41.7% 0% 0.0006
Fever [°C, mean (SD)] 37.9 (1.0) 37.6 (0.9) 1
Jaundice at any time (%) 9 (75) 18 (53) 0.3
Oliguria 91.7% 94.1% 1
Acute renal failure 100% 100% 1
Serum creatinine at baseline
[mg/dL, mean (SD)]
13.6 (6.4) 18.1 (8.4) 0.1
Systolic blood pressure [mmHg, mean (SD)] 135 (24.7) 127.8 (19.8) 0.4
Haemoglobin [g/dL, mean (SD)] 8.6 (2.3) 7.6 (2.7) 0.3
White blood cell count [/mm
3, mean (SD)] 23 860 (12 579) 16 701 (14 736) 0.17
Platelet count [/mm
3, mean (SD)] 212 600 (72 539) 226 969 (149 744) 0.7
ASAT [U/L, mean (SD)] 482.7 (860) 256.3 (313.9) 0.6
ALAT [U/L, mean (SD)] 363.8 (559.6) 164.3 (162.0) 0.9
Dialysis needed 58.3% 47.0% 0.7
Dialysis sessions [mean (SD)] 1.1 (1.0) 1.9 (2.3) 0.6
Time to death from admission [day, median (range)] 3 (1–6) –
Time to recovery from admission
[day, median (range)]
– 12 (6–32)
Serum creatinine at improvement
[mg/dL, mean (SD)]
– 2.4 (1.6)
ASAT, aspartate aminotransferase; ALAT, alanine aminotransferase.
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sion intervals of such patients were previously reported in
studies with only one to three patients [1–3]. In this study,
the responses of eight patients with concurrent SCA and
ESRD to Epo treatment were retrospectively investigated.
A total of eight patients (four males, four females; mean
age, 42 ± 11.7 years) with ESRD and SCA who were fol-
lowed up between May 2001 and October 2009 were stud-
ied, including one pre-dialysis (Stage 4–5), two peritoneal
dialysis and five haemodialysis patients. During the study
period, one patient died and one patient was transferred to
another centre after renal transplantation. The data of the
patients were obtained from the patient records and routine
monthly dialysis recordings. Unscheduled haemoglobin
measurements recorded in the emergency room during
painful episodes and control haemoglobin levels measured
after transfusions were recorded but not included in the
calculations. The means of the haemoglobin and ferritin
levels, transferrin saturation indices, blood transfusion re-
quirements and hospitalizations were recorded before and
after Epo treatment over a period of 12 months. The results
of pre- and post-Epo treatment were compared using the
paired t-test.
In four haemodialysis patients, treatment with epoetin
beta had been started after blood transfusions when hae-
moglobin levels rose to approximately 7–8 g/dL, with a
dosage of 75 U/kg/week. Despite this therapy, haemoglo-
bin concentrations fell to 5–5.5 g/dL in 2 months. There-
fore, the epoetin beta dosage was increased to and
maintained at 150 U/kg/week. The other four patients were
both started and maintained on Epo therapy at the upper
end of the dosage range allowed for ESRD patients, ac-
cording to guidelines. Haemoglobin levels of all the pa-
tients were recorded throughout the study period while
they were under the maximum maintenance Epo dosage
with the following results: 0.75 μg/kg/week s.c. for darbe-
poetin alpha (one pre-dialysis and two peritoneal dialysis
patients) and 150 U/kg/week s.c. for epoetin beta (five
haemodialysis patients). No patient was receiving iron
therapy and only one patient received the hydroxyurea
treatment with an adjusted ESRD dose (500 mg/day) dur-
ing the study period.
There was no significant difference between the means
of the haemoglobin (5.6 ± 0.4 vs 5.5 ± 0.4 g/dL) and fer-
ritin levels (>2000 vs >2000 ng/mL), transferrin saturation
indices (72.6 ± 19.5 vs 76.5 ± 21.2%), numbers of hospi-
talizations (5.5 times per year—min. 3, max. 8 vs 6.0 times
per year—min. 2, max. 9) and blood transfusion needs and
rates (minimum 1–2 U/2–3 months, maximum 1–3 U/1–
2 months) before and after Epo treatment.The haemoglobin
levels of the patients still decreased to between 4.0 and
4.5 g/dL once or twice during the year Epo was being ad-
ministered (Table 1). Therewas no newly developed throm-
boemboliceventinanyofthepatientsduringEpotreatment.
Epo treatment was continued (14 ± 2.2 months) in one
pre-dialysis and two peritoneal dialysis patients and was
ceasedinfivepatientsduetounresponsivenesstotreatment.
In one of the patients in whom Epo treatment was ceased,
the treatment had been administered from May 2001 to
September 2006, ceased in 2006 and the patient died in
2008. The mean time of Epo treatment in the other four
patients in whom Epo had been stopped due to unrespon-
siveness was 18 ± 6.3 months.
In this retrospective study, the unresponsiveness of Epo
treatment, resulting in target haemoglobin levels not being
reached in patients with concurrent SCA and ESRD, could
possibly be due to the fact that the precise cause of anae-
mia in this patient group is not Epo insufficiency. On the
other hand, since basal endogenous Epo levels in SCA pa-
tients are shown to be higher than in the normal popula-
tion, the Epo requirement may also be much higher than
for other ESRD patients following the development of re-
nal failure [4].
With regard to the variable individual response to Epo
treatment, until more precise data are available, with a
higher number of patients with SCA and ESRD from dif-
Table 1. Characteristics of SCA and ESRD patients and summary of Epo response
Patient
number
Patient
characteristics
1
Epo type and
dose (s.c.)
Hb,
pre-Epo (g/dl)
Hb, on
Epo (g/dl)
Minimum
Hb, on
Epo (g/dl)
2
Blood transfusion
need and rate
pre-Epo
Blood transfusion
need and rate
on Epo
1 32 years,
M, HD
Epoetin beta,
3 × 5000 U/week
6.4 5.9 4.0 16 U/year,
1–3 U per 1–2M
17 U/year,
1–3 U per 1–2M
2 41 years,
M, HD
Epoetin beta,
2 × 5000 U/week
5.7 5.6 4.2 10 U/year,
1–2 U per 1–2M
11 U/year,
1–2 U per 1–2M
3 33 years,
M, HD
Epoetin beta,
3 × 4000 U/week
5.1 6.2 4.5 9 U/year,
1–2Up e r2M
8 U/year,
1–2Up e r2M
4 43 years,
F, PD
Darbepoetin alpha,
50 μg/week
5.4 5.5 4.4 13 U/year,
1–2 U per 1–2M
12 U/year,
1–2 U per 1–2M
5 53 years,
F, PD
Darbepoetin alpha,
60 μg/week
5.6 5.3 4.5 11 U/year,
1–2Up e r2M
11 U/year,
1–2Up e r2M
6 65 years,
F, HD
Epoetin beta,
2 × 5000 U/week
6.1 5.7 4.3 14 U/year,
1–3 U per 1–2M
15 U/year,
1–3 U per 1–2M
7 38 years,
M, HD
Epoetin beta,
3 × 5000 U/week
5.3 5.2 4.0 12 U/year,
1–3 U per 1–2M
12 U/year,
1–3 U per 1–2M
8 31 years, F,
Stage 4–5
Darbepoetin alpha,
40 μg/week
5.6 5.2 4.5 8 U/year,
1–2Up e r2M
9 U/year,
1–2Up e r2M
U, units; M, months.
1Age, gender (male/female), haemodialysis (HD), peritoneal dialysis (PD).
2Minimum haemoglobin recorded in emergency room.
NDT Plus (2010) 329ferent centres, it would be appropriate to attempt treatment
with the maximum possible dose for a period and then to
stop this expensive treatment if the expected response can-
not be achieved.
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Marked improvement in renal function after rectal
cancer resection in a case of anti-neutrophil cytoplas-
mic autoantibody-negative pauci-immune crescentic
glomerulonephritis
Sir,
A small number of patients with pauci-immune crescentic
glomerulonephritis (CrGN) lack circulating anti-neutro-
phil cytoplasmic autoantibodies (ANCAs) [1], and the sig-
nificance and pathogenesis of this disorder are not fully
understood. A recent paper reported that ANCA-negative
pauci-immune CrGN might represent an independent dis-
ease entity, with distinctive features [2]. In contrast to the
many reports describing a strong relationship between neo-
plasms and glomerulopathies, i.e. membranous nephropa-
thy [3], there has been a limited number of reports
documenting a possible relationship with rapidly progres-
sive glomerulonephritis (RPGN). Serum ANCA levels also
tend to be positive in such cases (Table 1).
A 59-year-old malewas hospitalized because of rapid de-
teriorationinrenalfunctionoverthecourseofseveralweeks
(Figure 1). Renal impairment was not evident 7 months ear-
lier [serum creatinine (sCr), 78.8 μmol/L]. Although RPGN
wasindicated,neithermyeloperoxidase(MPO)-norprotein-
ase 3 (PR3)-ANCAwas detected in the serum by enzyme-
linked immunosorbent assay. A non-specific assay using a
commercialfluorescencedetectionkitalsofailedtodetectse-
rum ANCA. No other organinvolvement was evident.
Unexpectedly, a 4-cm rectal tumour was found concur-
rently and pathologically diagnosed as a well-differentiated
adenocarcinoma. Serum carcinoembryonic antigen (CEA),
carbohydrate antigen 19-9 (CA19-9), cancer antigen
125 (CA125) and alpha-fetoprotein (AFP) were all nega-
tive. Because the renal function deteriorated even further
(sCr, up to 289.4 μmol/L), low-dose oral steroid therapy,
i.e. 20 mg/day (0.28 mg/kg/day) prednisolone, was initia-
ted preoperatively based on the presumptive diagnosis of
RPGN.
Theprincipalfindingofthebiopsy,whichwasperformed
atDay13ofthesteroidtherapy,wasCrGN,with70–80%of
the glomeruli (total = 31 glomeruli) exhibiting fibrocellular
or fibrous crescents. No immunoglobulins were detected in
the glomeruli by immunofluorescent analysis.
Despite a temporary improvement in renal function af-
ter the low-dose prednisolone administration at the time of
biopsy, the sCr level started to rise again (Figure 1). Ste-
roid therapy was tapered off to reduce surgery-associated
risks, followed by successful resection of the rectal cancer
(pT3M0N1). The sCr level declined immediately after the
surgery without further medication.
Therelapseofprogressiverenalinsufficiencypriortoste-
roiddiscontinuationanditssignificantreversalimmediately
after the surgery suggest that tumour resection rather than
theshort-termlow-doseoralsteroidtherapywasresponsible
for the improvement of renal function. Hence, the present
Table 1. Published cases of RPGN associated with non-renal solid malignancies
Age (years), gender Organ Serum ANCA Citation
64, M Stomach Not mentioned Intern Med 2008; 47: 1237
57, M Stomach pANCA(−)/cANCA(−)
a Gastric Cancer 2003; 6:267
60, F Lung pANCA(+) Am J Kidney Dis 2000; 36: E24
64, M Stomach cANCA(+) Int Urol Nephrol 1994; 26: 579
62, M Lung cANCA(+) Clin Nephrol 1993; 40: 22
56, M Prostate cANCA(+) Clin Nephrol 1993; 40: 22
77, M Prostate pANCA(+) Clin Nephrol 1993; 40: 22
50, M Bladder cANCA(+) Clin Nephrol 1993; 40: 22
pANCA, perinuclear anti-neutrophil cytoplasmic autoantibodies; cANCA, cytoplasmic anti-neutrophil cytoplasmic autoantibodies.
aThe method for detection was not specifically described.
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